Black Diamond Therapeutics (BDTX) Shares Outstanding (2018 - 2026)

Black Diamond Therapeutics (BDTX) has reported Shares Outstanding (Entity) for 9 consecutive years, with $57.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Shares Outstanding (Entity) rose 0.98% year-over-year to $57.4 million; the trailing twelve-month figure through Jun 2026 stood at $57.4 million (up 0.98% YoY), and the FY2025 full-year result was $57.1 million, up 0.87% from the prior year.
• Shares Outstanding (Entity) was little changed at $57.4 million in Q2 2026 per BDTX's latest filing, from $57.3 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $57.4 million in Q2 2026 and bottomed at $36.3 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $49.2 million across 5 years, with a median of $54.5 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) rose 0.3% in 2022, then surged 54.4% in 2024.
• Over 5 years, Shares Outstanding (Entity) stood at $36.4 million in 2022, then surged by 41.75% to $51.6 million in 2023, then climbed by 9.68% to $56.6 million in 2024, then rose by 0.87% to $57.1 million in 2025, then increased by 0.54% to $57.4 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $57.4 million, $57.3 million, and $57.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.